The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient ...

Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...

AstraZeneca will resume a 300 million pound ($404 million) investment program in the U.K. seven months after freezing the ...

When it comes to GSK’s new dealmaking strategy of trying to outdo established blockbusters, CEO Luke Miels has told Fierce that oncology may offer the most tempting targets. | When it comes to GSK’s ...

GSK has finally called time on its pact with Mersana Therapeutics despite sinking $100 million to secure an option for an ...

AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. | AstraZeneca has scrapped an ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an ...

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

The FDA has released briefing documents detailing its concerns for AstraZeneca’s cancer drugs camizestrant and Truqap ahead ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to ...